Senseonics Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Senseonics Holdings is Tim Goodnow, benoemd in Dec2015, heeft een ambtstermijn van 8.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.59M, bestaande uit 17.1% salaris en 82.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.84% van de aandelen van het bedrijf, ter waarde $ 1.66M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.1 jaar en 8.2 jaar.

Belangrijke informatie

Tim Goodnow

Algemeen directeur

US$3.6m

Totale compensatie

Percentage CEO-salaris	17.1%
Dienstverband CEO	8.9yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tim Goodnow's beloning veranderd ten opzichte van Senseonics Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$80m
Mar 31 2024	n/a	n/a	-US$81m
Dec 31 2023	US$4m	US$613k	-US$60m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	US$57m
Dec 31 2022	US$4m	US$586k	US$142m
Sep 30 2022	n/a	n/a	US$215m
Jun 30 2022	n/a	n/a	US$318m
Mar 31 2022	n/a	n/a	US$34m
Dec 31 2021	US$3m	US$569k	-US$302m
Sep 30 2021	n/a	n/a	-US$489m
Jun 30 2021	n/a	n/a	-US$555m
Mar 31 2021	n/a	n/a	-US$382m
Dec 31 2020	US$3m	US$552k	-US$175m
Sep 30 2020	n/a	n/a	-US$109m
Jun 30 2020	n/a	n/a	-US$105m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$2m	US$536k	-US$116m
Sep 30 2019	n/a	n/a	-US$87m
Jun 30 2019	n/a	n/a	-US$100m
Mar 31 2019	n/a	n/a	-US$101m
Dec 31 2018	US$2m	US$536k	-US$94m
Sep 30 2018	n/a	n/a	-US$103m
Jun 30 2018	n/a	n/a	-US$88m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$2m	US$520k	-US$59m

Compensatie versus markt: De totale vergoeding ($USD 3.59M ) Tim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).

Compensatie versus inkomsten: De vergoeding van Tim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Tim Goodnow (62 yo)

8.9yrs

Tenure

US$3,589,760

Compensatie

Dr. Timothy T. Goodnow, also known as Tim, Ph D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Goodnow	President	8.9yrs	US$3.59m	0.84% $ 1.7m
Mukul Jain	Chief Operating Officer	7.8yrs	US$1.56m	0.32% $ 640.0k
Kenneth Horton	General Counsel & Corporate Development Advisor	7.1yrs	US$1.31m	0.21% $ 411.6k
Francine Kaufman	Chief Medical Officer & Director	5.7yrs	geen gegevens	0.19% $ 376.8k
Frederick Sullivan	CFO, Secretary & Treasurer	2.2yrs	geen gegevens	0.092% $ 182.4k

7.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SENS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Goodnow	President	8.9yrs	US$3.59m	0.84% $ 1.7m
Francine Kaufman	Chief Medical Officer & Director	5yrs	geen gegevens	0.19% $ 376.8k
Douglas Roeder	Independent Non-Management Director	8.9yrs	US$174.75k	0.15% $ 289.3k
Edward Fiorentino	Independent Non-Management Director	8.9yrs	US$169.00k	0.16% $ 311.4k
Stephen DeFalco	Independent Chairman	8.9yrs	US$210.00k	0.29% $ 569.2k
Steven Edelman	Independent Non-Management Director	8.2yrs	US$164.00k	0.14% $ 285.9k
Douglas Prince	Independent Non-Management Director	8.9yrs	US$182.50k	0.12% $ 235.6k
Brian Hansen	Director	less than a year	geen gegevens	geen gegevens
Anthony Raab	Independent Non-Management Director	4.1yrs	US$152.50k	0.080% $ 157.8k
Sharon Larkin	Independent Non-Management Director	2.9yrs	US$159.00k	0.046% $ 91.2k
Koichiro Sato	Director	1.5yrs	geen gegevens	geen gegevens

8.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SENS wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).

Senseonics Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Independent Non-Management Director recently bought US$162k worth of stock

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Senseonics Holdings, Inc. Announces CFO Transition

Chief Operating Officer notifies of intention to sell stock

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Recent updates

New minor risk - Shareholder dilution

Senseonics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $16 million.

Senseonics Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Mercy Places First Commercial Eversense 365

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Senseonics Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Senseonics Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration

Senseonics Holdings, Inc. to Report Q1, 2024 Results on May 13, 2024

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

Consensus revenue estimates decrease by 22%

Senseonics Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Independent Non-Management Director recently bought US$162k worth of stock

Price target decreased by 18% to US$1.67

New minor risk - Profitability

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Senseonics Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 29%

Price target increased by 35% to US$2.75

Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Consensus estimates of losses per share improve by 33%

Price target increased by 19% to US$2.50

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 33%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Senseonics Holdings, Inc. Revises Revenue Guidance for Full Year 2022

Senseonics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Senseonics Holdings, Inc. Announces CFO Transition

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Chief Operating Officer notifies of intention to sell stock

Senseonics Holdings Inc. Announces Positive Coverage Decision for Eversense E3 CGM from Anthem

Investor sentiment improved over the past week

Senseonics Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$2.10

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Announces European Approval of the Next-Generation Eversense E3 Continuous Glucose Monitoring System

Consensus revenue estimates increase by 23%

Price target increased to US$4.25

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Senseonics Holdings, Inc. Announces the First Patient Implant of the Eversense E3 CGM System in the U.S

Independent Non-Management Director notifies of intention to sell stock

Consensus revenue estimates fall by 13%

Full year 2021 earnings: EPS misses analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Price target increased to US$4.17

President recently sold US$1.1m worth of stock

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months

Senseonics Holdings, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Chief Medical Officer & Director notifies of intention to sell stock

Third quarter 2021 earnings released: EPS US$0.096 (vs US$0.099 loss in 3Q 2020)

Independent Non-Management Director exercised options and sold US$410k worth of stock